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INTRODUCTION 
 
The rising prevalence of gestational diabetes is concerning because of the risk of 
pregnancy complications such as macrosomia, shoulder dystocia, caesarean section 
and neonatal hypoglycaemia and also because of the risk to the mother and 
offspring of diabetes and cardiovascular disease in later life [1][2][3]. Changes in the 
diagnostic criteria for GDM, the obesity epidemic, increasing maternal age and 
unhealthy lifestyles have all been implicated in the increasing prevalence of GDM [4] 
[5]. 
 
Identifying women at greatest risk of GDM early in their pregnancy would allow 
lifestyle modification interventions and possibly drug treatments to be implemented in 
order to reduce the risk of complications [6]. Metformin, for example, can be used to 
reduce the risk of GDM in women with polycystic ovaries [7].  
 
Various strategies are adopted to detect overt or gestational diabetes in pregnancy 
depending on the local prevalence of diabetes. Some centres in the UK have 
adopted the IADPSG strategy which recommends universal testing though our local 
policy was to continue using WHO criteria [4] . Our current policy of GDM screening 
is based on selective screening  of women at high risk of GDM based on (i) maternal 
age (ii) body mass index (BMI), (iii) history of polycystic ovarian syndrome as defined 
by the Rotterdam criteria [8], (iv) family history of diabetes (v) previous GDM (vi) 
ethnicity and (vii) previous macrosomia. Selective screening using risk factors above 
has low sensitivity (50-69%) and specificity (58-68%) and in one study, 39% of 
women with GDM would have been missed if only selective risk factor testing had 
been used [9]. Better selection processes for selective screening may reduce the 
need for oral glucose tolerance testing in women at low risk with resulting savings in 
costs and in burdensome diagnostic testing. 
 
Obesity is a strong predictor for GDM with Odds Ratios compared with normal 
weight women of about 3 for women with Class I obesity [10] and  5-8 for Class II 
and III obesity [11]. Nevertheless only 24% of Class I obese [12] or Class II and III 
obese [13] women developed GDM in the control arms of two recent prospective 
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trials investigating the possible beneficial effects of metformin in these women.  
Abdominal obesity may be a better predictor both for GDM and future development 
of diabetes outside pregnancy [14] [10]. 
 
In a prospective study of 302 obese pregnant women, we found that central obesity 
as assessed by early pregnancy waist-hip ratio (WHR) and visceral fat mass (VFM) 
measured by bioimpedance was an independent predictor of GDM in addition to 
classical risk factors [15].    
 
The aim of this study was to develop a mathematical model to accurately predict 
GDM in obese pregnant women in early pregnancy. We used Principal Component 
Analysis (PCA) initially but since the PCA showed no clear clustering of the GDM 
and non-GDM groups, machine learning using decision tree and random forests 
were used.  
 
Patients and methods 
The London-Surrey Borders Research Ethics committee advised us that ethical 
approval is not required for the study as all women would only undergo routine 
clinical investigations and management. No study specific procedure is undertaken 
on any of the participants. 
 
Details of the study methods have been previously published [15]. In brief, we 
enrolled 302 obese pregnant women with no established diabetes attending the 
weight management clinic at St Helier Hospital, Carshalton, Surrey, UK in 2010-
2011. The median age of these women was 31 years (range 26-34 years), the 
median BMI was 38.2 kg/m2  (range 36.1-41.4 kg/m2) and the median visceral fat 
mass (VFM) was 182.8 units (range 164.3-207.7 units). Seventy four point five per 
cent of the women were Caucasian. All women underwent 75 g oral glucose 
tolerance test between 24 and 28 weeks of gestation. GDM was defined by the 1999 
WHO criteria [16]. Seventy two of the 302 enrolled women (23.8%) subsequently 
developed GDM and were medically managed in the joint antenatal obstetric and 
diabetic clinic by a standard protocol. All women underwent body composition 
analysis at booking (median gestation (weeks): 15 [14-17]) by Direct Segmental 
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Multi-Frequency Bioelectrical Impedance Analysis Method (DSM- BIA Method) using 
an Inbody 720R machine. This method is based on the electric resistance difference 
between the fat and other components [17]. The device measures body mass index, 
waist/ hip ratio, lean body mass, total percentage body fat (PBF) and Visceral Fat 
Area. The InBody 720 has been validated and correlates well with intraabdominal fat 
area assessed by CT scan [18] and DEXA [19]. It has been also been shown to be 
safe in the second and third trimesters of pregnancy and has also been validated 
against deuterium and hydro-densitometry techniques for body composition analysis 
[20][21].  
 
Data mining and analysis 
The dataset consisted of the following variables; maternal age, weight, body mass 
index, percentage body fat, visceral fat mass, lean body mass, history of polycystic 
ovarian syndrome, family history of diabetes, history of hypertension and previous 
macrosomia. Principal Component Analysis (PCA) was performed on this dataset. 
PCA is a multivariate analysis for clustering input data according to their variance. 
PCA showed no clear clustering of the GDM and non-GDM groups. We then applied 
decision tree and random forests algorithms to the data after feeding the computer 
programme with the training dataset to recognise the presence or absence of 
gestational diabetes. This process is termed supervised machine learning [22] [23] 
[24].  
 
A decision tree algorithm classifies data items by asking a series of questions about 
the features associated with the items. Each question is contained in a node, and 
every internal node points to one child node for each positive answer to its question. 
There is a hierarchy in the questioning, encoded as a tree. In its simplest form, yes-
or-no questions are asked, and each internal node has a “yes” child and a “no “child. 
An item is sorted into a class as it passes down from the topmost node, the root, to a 
node without children, a leaf, depending on the answers. The item is then assigned 
to the class that has been associated with the leaf it reaches. If trained on high 
quality data, decision trees can make very accurate predictions [23]. 
 
Random Forest (RF) is an ensemble algorithm of decision trees aggregated 
together. This method constructs multiple versions of the training data by sampling 
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with replacement (bootstrapping), and combining the machine learning algorithms to 
make predictions [21].  
 
RF was implemented with 200 trees using the “randomForest” function from the 
“randomForest” package in R [25]. The performance of the developed model was 
validated using the Monte Carlo cross validation method [26]. For K=100, the 
samples from each dataset were randomly distributed into training and testing 
datasets in 100 different splits. Then, the performance was calculated as an average 
of the performance of the 100 models. Firstly, the input dataset (n = 302) was 
randomly split over 100 iterations into a training dataset, which contained 70% of the 
samples (n = 227), and a testing dataset (n = 75) composed by the remaining 
samples. The training dataset was then used to build the model while the testing 
dataset was used to calculate the performance of such model. As the performance is 
calculated as a mean of 100 individually trained and optimised models, the outcome 
is less likely to suffer from optimistic prediction accuracy and/or over-fitting. 
 
 
RESULTS 
Mathematical modelling 
The optimisation confusion matrix (Figure 1) indicates that the model achieved 100% 
classification accuracy where all 227 training samples were correctly classified. The 
model validation achieved an initial prediction accuracy of 81.13%; where 61 out of 
75 samples were correctly predicted (Figure 1). Upon running a series of 200 
iterations, while randomly reshuffling samples within the training and testing subsets, 
the model stabilised after 20 iterations as shown from the performance accumulative 
mean, achieving a mean performance of 77.53%. However, 14 patients were 
wrongly classified.  
Visceral fat mass emerged as the most important variable for predicting GDM by the 
Random Forest method as shown in Figure 2 and Figure 3. This was followed by 
BMI, weight, PBF and waist hip ratio. The less important variables were family 
history of diabetes, hypertension, previous big baby and history of polycystic ovarian 
syndrome. The decision tree used a value of VFM < 210 as the first split in the 
decision tree.   
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DISCUSSION 
 
In this analysis, VFM emerged as the most important variable in determining the risk 
of GDM, followed by BMI, weight, PBF and waist: hip ratio. Traditional predictors like 
previous GDM, history of polycystic ovarian syndrome, family history of diabetes and 
previous big baby were less important. These results add to the growing evidence of 
the importance of central obesity and in particular, visceral fat mass in the 
development of GDM. 
 
The model correctly classified all 227 training samples and achieved a mean 
validation performance of 77.53% thereby providing good prediction accuracy. 
However, even though 97% of the no GDM were classified correctly, only one third 
of the GDM were correctly classified. Since only 24% of patients developed GDM in 
the original training dataset, there was an unbalanced distribution of samples among 
both classes, resulting in a slight bias in the model prediction towards the no GDM 
class. A larger training database with consequently more positive GDM would be 
required for training the model better thereby improving the predictive performance 
of the model. 
 
To our knowledge, this is the first attempt to create a mathematical model to predict 
GDM incorporating VFM. Traditional predictors based on maternal history are easy 
to measure and widely applicable. The importance of central obesity and features of 
the metabolic syndrome in the development of GDM has long been recognised (24).  
A strong association between measures of abdominal obesity (waist circumference, 
WHR and CT-assessed intra-abdominal fat area) and the development of type 2 
diabetes is also well established [14] . Measuring VFM by bioimpedance is simple 
and can easily be done in the clinical setting. In our experience, midwives very 
quickly learn how to perform this measurement and the test takes less than 5 
minutes. We have previously reported that VFM but not PBF correlates with fasting 
glucose and HbA1c particularly in women developing GDM [15] This finding 
emphasizes the importance of metabolically active visceral fat. 
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The clinical significance of this study is the potential for early and personalised risk 
stratification for GDM allowing low risk women to avoid unnecessary diagnostic 
testing, repeated clinic visits and additional growth scans. Conversely those at high 
risk can start lifestyle interventions early to reduce the risk of complications.  
 
The strength of this study is that we measured a range of clinically relevant and 
novel predictors of GDM simultaneously rather than one novel measure measured in 
isolation. As such, the model created has greater validity. We also acknowledge 
limitations. The sample size was relatively small and a larger dataset will be needed 
to further train the model and improve its accuracy. In addition, our dataset was 
predominantly Caucasian and hence we were unable to include ethnicity in the 
model.  
In summary, existing prog ostic models for GDM lack a strong predictive value and 
are not commonly used in routine clinical care nor are they recommended by current 
clinical guidelines. The addition of VFM in early pregnancy in the predictive model 
helps discriminate between high and low risk pregnancies but this need to be 
confirmed in larger studies with diverse populations. 
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Figure 1: 0 represents no GDM and 1 represents GDM. The figure on the left hand side is the Optimisation 
Confusion matrix for prediction of GDM. The model achieved 100% classification accuracy  where all 227 
training samples were correctly classified as GDM or no GDM. The figure on the right hand side is the 
Validation Confusion matrix. The model predicted 61 out of 75 samples correctly achieving an initial 
prediction accuracy of 81%.  
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Figure 2: Ranking of variables in predicting GDM. Visceral Fat Area emerged as the most important input 
variable followed by BMI, weight, Percentage Body Fat (PBF) and Waist Hip ratio (WHR). Less important 
variables included family history of diabetes, hypertension, previous big baby and history of polycystic 
ovarian syndrome.  
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Figure 3: Decision tree in predicting GDM. Visceral Fat Area emerged as the most important input variable. 
The decision tree used a value of VFM < 210 as the first split in the decision tree.    
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